Aridis Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017	2016
Cash & Equivalents	4.88	19.99	8.23	20.9	24.24	25.1	22.29
Cash & Cash Equivalents	4.88	19.99	8.23	20.9	24.24	25.1	22.29
Cash Growth	-75.60%	142.78%	-60.61%	-13.78%	-3.42%	12.58%	-
Receivables	1.24	0.24	0.37	0.41	1.66	0	0.07
Inventory	0	-0.24	-0.37	-0.41	-4.11	0	0
Other Current Assets	5.51	6.81	6.89	7.07	2.45	0.24	0.05
Total Current Assets	11.63	26.8	15.12	27.97	24.24	25.34	22.41
Property, Plant & Equipment	2.15	1.36	1.26	1.01	1.27	0.75	0.04
Long-Term Investments	0	0	0	0.01	0.96	0	0
Intangible Assets	0.02	0.02	0.03	0.03	0.04	0.04	0.05
Other Long-Term Assets	0.91	0.93	0.99	0.56	5.11	0.35	0.04
Total Long-Term Assets	3.07	2.31	2.27	1.6	7.37	1.14	0.13
Total Assets	14.7	26.8	15.12	27.97	31.61	26.48	22.54
Accounts Payable	2.31	5.24	1.89	1.76	2.33	0.93	0.68
Deferred Revenue	20.17	20.84	18.75	14.6	0.02	0.12	0
Current Debt	4.84	0.7	0.44	0	2.49	0	0
Other Current Liabilities	9.58	6.57	1.37	2.97	0.46	2.12	1.72
Total Current Liabilities	36.9	33.35	22.44	19.33	5.3	3.17	2.4
Long-Term Debt	1.29	5.28	0.28	0	0	0	0
Other Long-Term Liabilities	0.74	1.28	1.08	5	0	11.87	6.37
Total Long-Term Liabilities	2.03	6.56	1.36	5	0	11.87	6.37
Total Liabilities	38.93	40.91	23.8	24.33	5.3	15.04	8.76
Total Debt	6.13	5.98	0.72	0	0	0	0
Debt Growth	2.54%	736.08%	-	-	-	-	-
Common Stock	0	0	0	0	0	0	0
Retained Earnings	-195.67	-165.3	-123.1	-100.77	-71.09	-47.63	-20.18
Comprehensive Income	5.05	0	0	0	-0.49	-0.22	-0.16
Shareholders' Equity	-24.23	-14.11	-8.68	3.64	26.31	11.44	13.78
Total Liabilities and Equity	14.7	26.8	15.12	27.97	31.61	26.48	22.54
Net Cash / Debt	-1.25	14.01	7.52	20.9	24.24	25.1	22.29
Net Cash / Debt Growth	-	86.35%	-64.03%	-13.78%	-3.42%	12.58%	-
Net Cash Per Share	-0.07	1.14	0.82	2.47	7.70	3.18	2.83
Working Capital	-25.27	-6.55	-7.32	8.64	18.94	22.17	20.01
Book Value Per Share	-1.29	-1.15	-0.95	0.43	8.36	1.45	1.75

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.